NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience

Bagley, Alexander F.; Ludmir, Ethan B.; Maitra, Anirban; Minsky, Bruce D.; Smith, Grace L.; Das, Prajnan; Koong, Albert C.; Holliday, Emma B.; Taniguchi, Cullen M.; Katz, Matthew H.; Tamm, Eric P.; Wolff, Robert A.; Overman, Michael J.; Patel, Shivani; Kim, Michael P.; Tzeng, Ching‐Wei D.; Ikoma, Naruhiko; Bhutani, Manoop S.; Koay, Eugene J.

doi:10.1016/j.ctro.2021.12.012

Cited by 32 publications

(22 citation statements)

References 12 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This concept is being utilised clinically in CT-guided radiation therapy by NBTXR3, which is a functionalised hafnium nanoparticle currently in clinical trials for multiple sites (Hoffmann et al 2021). On treatment imaging of NBTXR3 can be utilised to monitor tumour uptake and retention of the nanoparticle and for dose enhancement (Bagley et al 2022).…”

Section: The Role For Theranostic Nanoparticlesmentioning

confidence: 99%

Nanoparticles for MRI-guided radiation therapy: a review

et al. 2022

View full text Add to dashboard Cite

The development of nanoparticle agents for MRI-guided radiotherapy is growing at an increasing pace, with clinical trials now underway and many pre-clinical evaluation studies ongoing. Gadolinium and iron-oxide-based nanoparticles remain the most clinically advanced nanoparticles to date, although several promising candidates are currently under varying stages of development. Goals of current and future generation nanoparticle-based contrast agents for MRI-guided radiotherapy include achieving positive signal contrast on T1-weighted MRI scans, local radiation enhancement at clinically relevant concentrations and, where applicable, avoidance of uptake by the reticuloendothelial system. Exploiting the enhanced permeability and retention effect or the use of active targeting ligands on nanoparticle surfaces is utilised to promote tumour uptake. This review outlines the current status of promising nanoparticle agents for MRI-guided radiation therapy, including several platforms currently undergoing clinical evaluation or at various stages of the pre-clinical development process. Challenges facing nanoparticle agents and possible avenues for current and future development are discussed.

show abstract

Section: The Role For Theranostic Nanoparticlesmentioning

confidence: 99%

Nanoparticles for MRI-guided radiation therapy: a review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…While the use of nanoparticles as RT sensitizers can largely reduce the high RT dose from 20-60 Gy in clinical settings [114] to below 10 Gy, the threshold causes significant vascular damage [115]. Some cases can be reduced to 2 Gy or below, such as Au at 4-6 Gy [116], MnO2 at 3 Gy [117], BSA-decorated gold nanoclusters at 6 Gy [118], Hf, a first-in-class radioenhancer known as NBTXR3 (Nanobiotix), at 2-5 Gy [119][120][121], Bi at 9 Gy [122], Bi2O3 NPs at 6 Gy [123,124], Bi@BSA at 4 Gy [125], FePt nanoparticles below 8 Gy [126], Gd-polysiloxane NPs (AGuIX®) at 2-7 Gy [127,128], and PbS/CdS QDs at 8 Gy [87]. Indeed, controlling the energy dose to regulate cancer eradication and immune activation is an interesting issue.…”

Section: The Advantages Challenges and Future Expectations For Nanote...mentioning

confidence: 99%

Nanoparticles augment the therapeutic window of RT and immunotherapy for treating cancers: pivotal role of autophagy

Wu¹,

Chen²,

Chiu³

et al. 2023

Theranostics

View full text Add to dashboard Cite

Immunotherapies are now emerging as an efficient anticancer therapeutic strategy. Cancer immunotherapy utilizes the host's immune system to fight against cancer cells and has gained increasing interest due to its durable efficacy and low toxicity compared to traditional antitumor treatments, such as chemotherapy and radiotherapy (RT). Although the combination of RT and immunotherapy has drawn extensive attention in the clinical setting, the overall response rates are still low. Therefore, strategies for further improvement are urgently needed. Nanotechnology has been used in cancer immunotherapy and RT to target not only cancer cells but also the tumor microenvironment (TME), thereby helping to generate a long-term immune response. Nanomaterials can be an effective delivery system and a strong autophagy inducer, with the ability to elevate autophagy to very high levels. Interestingly, autophagy could play a critical role in optimal immune function, mediating cell-extrinsic homeostatic effects through the regulation of danger signaling in neoplastic cells under immunogenic chemotherapy and/or RT. In this review, we summarize the preclinical and clinical development of the combination of immunotherapy and RT in cancer therapy and highlight the latest progress in nanotechnology for augmenting the anticancer effects of immunotherapy and RT. The underlying mechanisms of nanomaterial-triggered autophagy in tumor cells and the TME are discussed in depth. Finally, we suggest the implications of these three strategies combined together to achieve the goal of maximizing the therapeutic advantages of cancer therapy and show recent advances in biomarkers for tumor response in the evaluation of those therapies.

show abstract

“…There are several clinical trials that investigate the efficacy of NBTXR3 in an array of cancer types ( Table 3 ). In trials on pancreatic ductal adenocarcinoma ( Figure 7 C) [ 165 ] and locally advanced squamous cell carcinoma ( Figure 7 D) [ 166 ], the accumulation and retention of NBTXR3 in tumor were visualized by CT, which is valuable in evaluating the biodistribution of injected NPs and confirming persistence of NBTXR3 during the entire duration of radiotherapy.…”

Section: Strategies Of Constructing Nanotheranosticsmentioning

confidence: 99%

“…Adapted based on Ref. [ 165 ]. ( D ) CT scans showing intratumoral localisation of NBTXR3 at 24 h after injection and after radiotherapy (RT) in a patient with locally advanced squamous cell carcinoma.…”

Section: Figurementioning

confidence: 99%

Nanotheranostics for Image-Guided Cancer Treatment

et al. 2022

View full text Add to dashboard Cite

Image-guided nanotheranostics have the potential to represent a new paradigm in the treatment of cancer. Recent developments in modern imaging and nanoparticle design offer an answer to many of the issues associated with conventional chemotherapy, including their indiscriminate side effects and susceptibility to drug resistance. Imaging is one of the tools best poised to enable tailoring of cancer therapies. The field of image-guided nanotheranostics has the potential to harness the precision of modern imaging techniques and use this to direct, dictate, and follow site-specific drug delivery, all of which can be used to further tailor cancer therapies on both the individual and population level. The use of image-guided drug delivery has exploded in preclinical and clinical trials although the clinical translation is incipient. This review will focus on traditional mechanisms of targeted drug delivery in cancer, including the use of molecular targeting, as well as the foundations of designing nanotheranostics, with a focus on current clinical applications of nanotheranostics in cancer. A variety of specially engineered and targeted drug carriers, along with strategies of labeling nanoparticles to endow detectability in different imaging modalities will be reviewed. It will also introduce newer concepts of image-guided drug delivery, which may circumvent many of the issues seen with other techniques. Finally, we will review the current barriers to clinical translation of image-guided nanotheranostics and how these may be overcome.

show abstract

NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience

Cited by 32 publications

References 12 publications

Nanoparticles for MRI-guided radiation therapy: a review

Nanoparticles for MRI-guided radiation therapy: a review

Nanoparticles augment the therapeutic window of RT and immunotherapy for treating cancers: pivotal role of autophagy

Nanotheranostics for Image-Guided Cancer Treatment

Contact Info

Product

Resources

About